News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,260 Results
Type
Article (14354)
Company Profile (105)
Press Release (259793)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88387)
Career Advice (465)
Deals (15409)
Drug Delivery (75)
Drug Development (36800)
Employer Resources (50)
FDA (6403)
Job Trends (6238)
News (150946)
Policy (14168)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (445)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23335)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (99)
Approvals (6591)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (151)
Best Places to Work (4372)
BIOSECURE Act (9)
Biosimilars (130)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1317)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (150)
Cervical cancer (9)
Clinical research (32090)
Collaboration (725)
Compensation (325)
Complete response letters (33)
COVID-19 (779)
CRISPR (43)
C-suite (433)
Cystic fibrosis (58)
Data (1821)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1382)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (119)
Drug shortages (13)
Duchenne muscular dystrophy (80)
Earnings (33508)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (39019)
Executive appointments (529)
FDA (7500)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (428)
Gene editing (70)
Generative AI (18)
Gene therapy (165)
GLP-1 (440)
Government (1410)
Grass and pollen (4)
Guidances (164)
Healthcare (3594)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (71)
Immuno-oncology (14)
Indications (53)
Infectious disease (843)
Inflammatory bowel disease (76)
Inflation Reduction Act (8)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5915)
IRA (35)
Job creations (2059)
Job search strategy (374)
JPM (29)
Kidney cancer (9)
Labor market (28)
Layoffs (208)
Leadership (8)
Legal (3465)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (68)
Medical device (1317)
Medtech (1324)
Mergers & acquisitions (9913)
Metabolic disorders (436)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (37)
Neuroscience (887)
Neurotech (1)
NextGen: Class of 2026 (1593)
Non-profit (603)
Now hiring (17)
Obesity (227)
Opinion (147)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29786)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8312)
Phase 2 (13547)
Phase 3 (12247)
Pipeline (1910)
Policy (139)
Postmarket research (1412)
Preclinical (3347)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2662)
Recruiting (18)
Regulatory (10975)
Reports (15)
Research institute (575)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (8)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1649)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (141)
Women's health (27)
Worklife (4)
Date
Last 7 days (177)
Last 30 days (704)
Last 365 days (10423)
2026 (951)
2025 (10730)
2024 (12521)
2023 (14265)
2022 (19584)
2021 (20115)
2020 (19064)
2019 (14907)
2018 (11743)
2017 (13924)
2016 (13175)
2015 (15517)
2014 (12430)
2013 (10609)
2012 (11405)
2011 (11934)
2010 (10901)
Location
Africa (320)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20951)
Australia (2691)
California (3179)
Canada (1481)
China (550)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (41013)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (349)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2590)
Michigan (46)
Minnesota (166)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1398)
New Mexico (7)
New York (907)
North Carolina (619)
North Dakota (2)
Northern California (1449)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (510)
South Carolina (10)
Southern California (1387)
Tennessee (53)
Texas (455)
United States (12681)
Utah (59)
Virginia (160)
Washington D.C. (43)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
274,260 Results for "teva pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Teva Brings First GLP-1 Generic for Obesity, Targets Novo’s Saxenda
In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.
August 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Teva Canada Announces Strategic Partnership with Novartis Canada to Relaunch Mayzent® for Multiple Sclerosis Patients in Canada
February 2, 2026
·
2 min read
Press Releases
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 12, 2026
·
9 min read
Press Releases
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
3 min read
Press Releases
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
December 10, 2025
·
7 min read
Press Releases
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
February 5, 2026
·
4 min read
Press Releases
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
January 28, 2026
·
65 min read
Press Releases
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
January 12, 2026
·
7 min read
Press Releases
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
November 26, 2025
·
6 min read
Press Releases
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
December 15, 2025
·
2 min read
1 of 27,426
Next
